{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:48:52Z","timestamp":1791413332940,"version":"4.3.3"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"crossref"}]},{"name":"United States Defense Threat Reduction Agency","award":["HDTRA1-13-C-0018"],"award-info":[{"award-number":["HDTRA1-13-C-0018"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI109762"],"award-info":[{"award-number":["U19AI109762"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"crossref","award":["HHSO100201400009C"],"award-info":[{"award-number":["HHSO100201400009C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.coviro.2016.01.006","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T00:00:23Z","timestamp":1453939223000},"page":"45-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Antibody therapeutics for Ebola virus disease"],"prefix":"10.1016","volume":"17","author":[{"given":"Larry","family":"Zeitlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J","family":"Whaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene G","family":"Olinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangguo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P","family":"Kobinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2016.01.006_bib0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","article-title":"Return to the past: the case for antibody-based therapies in infectious diseases","volume":"21","author":"Casadevall","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2016.01.006_bib0160","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1286-4579(00)00355-5","article-title":"Preventing infectious disease with passive immunization","volume":"2","author":"Zeitlin","year":"2000","journal-title":"Microbes Infect"},{"key":"10.1016\/j.coviro.2016.01.006_bib0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3201\/eid0501.990107","article-title":"Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases","volume":"5","author":"Zeitlin","year":"1999","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2016.01.006_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00063030-200721010-00001","article-title":"Trends in the development and approval of monoclonal antibodies for viral infections","volume":"21","author":"Reichert","year":"2007","journal-title":"BioDrugs"},{"key":"10.1016\/j.coviro.2016.01.006_bib0175","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nbt0905-1073","article-title":"Monoclonal antibody successes in the clinic","volume":"23","author":"Reichert","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coviro.2016.01.006_sbref0180","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients","volume":"179","author":"Mupapa","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.01.006_bib0185","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1086\/520587","article-title":"Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates","volume":"196","author":"Jahrling","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.01.006_bib0190","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1086\/514294","article-title":"Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections","volume":"179","author":"Kudoyarova-Zubavichene","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.01.006_bib0195","first-page":"135","article-title":"Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses","volume":"11","author":"Jahrling","year":"1996","journal-title":"Arch Virol Suppl"},{"key":"10.1016\/j.coviro.2016.01.006_bib0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/514310","article-title":"Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections","volume":"179","author":"Jahrling","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.01.006_bib0205","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.01.006_bib0210","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1128\/JVI.76.12.6408-6412.2002","article-title":"Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody","volume":"76","author":"Parren","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.01.006_sbref0215","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1371\/journal.ppat.0030009","article-title":"Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys","volume":"3","author":"Oswald","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.01.006_sbref0220","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1073\/pnas.1200409109","article-title":"Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease","volume":"109","author":"Dye","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.coviro.2016.01.006_bib0225","doi-asserted-by":"crossref","first-page":"e36192","DOI":"10.1371\/journal.pone.0036192","article-title":"Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever","volume":"7","author":"Marzi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2016.01.006_bib0230","doi-asserted-by":"crossref","first-page":"138ra181","DOI":"10.1126\/scitranslmed.3003876","article-title":"Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies","volume":"4","author":"Qiu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2016.01.006_bib0235","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.1213709109","article-title":"Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques","volume":"109","author":"Olinger","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.01.006_bib0240","doi-asserted-by":"crossref","first-page":"20690","DOI":"10.1073\/pnas.1108360108","article-title":"Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant","volume":"108","author":"Zeitlin","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.coviro.2016.01.006_bib0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006608","article-title":"Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail","volume":"5","author":"Pettitt","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2016.01.006_sbref0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.01.006_sbref0255","series-title":"Ethical considerations for use of unregistered interventions for Ebola virus disease","author":"WHO","year":"2014"},{"key":"10.1016\/j.coviro.2016.01.006_bib0260","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1542\/peds.2005-0629","article-title":"Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns","volume":"117","author":"Lanari","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.coviro.2016.01.006_bib0265","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/INF.0000000000000240","article-title":"Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness","volume":"33","author":"Ramilo","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.coviro.2016.01.006_bib0270","first-page":"517","article-title":"Virus excretion in smallpox. 1. Excretion in the throat, urine, and conjunctiva of patients","volume":"48","author":"Sarkar","year":"1973","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.coviro.2016.01.006_bib0275","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiv304","article-title":"The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Medecins Sans Frontieres Ebola Case Management Centre, Kailahun, Sierra Leone, June\u2013October 2014","author":"Fitzpatrick","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.01.006_bib0280","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2016.01.006_bib0285","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.vaccine.2006.09.076","article-title":"Protective efficacy of neutralizing antibodies against Ebola virus infection","volume":"25","author":"Takada","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.01.006_bib0290","doi-asserted-by":"crossref","first-page":"158ra146","DOI":"10.1126\/scitranslmed.3004582","article-title":"Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates","volume":"4","author":"Wong","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2016.01.006_bib0295","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1056\/NEJMp1414145","article-title":"Evaluating Ebola therapies \u2013 the case for RCTs","volume":"371","author":"Cox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2016.01.006_sbref0300","first-page":"194","article-title":"Normal serum IgE and IgG antibody levels in adult male cynomolgus monkeys","volume":"38","author":"Biagini","year":"1988","journal-title":"Lab Anim Sci"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T13:13:06Z","timestamp":1600089186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625716000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":30,"alternative-id":["S1879625716000092"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2016.01.006","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody therapeutics for Ebola virus disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2016.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}